Almost all people with axial spondyloarthritis (axSpA) who had worsening disease severity after stopping Taltz (ixekizumab) saw improvements after restarting the therapy, according to data from a Phase 3 withdrawal study. The majority (71%) reached a state of disease remission after restarting treatment. These findings provide important information about…
The European Medicines Agency has agreed to review UCB’s applications seeking the approval of bimekizumab for adults with active axial spondyloarthritis (axSpA). Axial spondyloarthritis is a type of inflammatory arthritis affecting the joints of the spine, chest, and pelvis. Ankylosing spondylitis (AS) is a severe type of axSpA,…
Ankylosing spondylitis (AS) led to bone formation that resulted in the rare complete fusion of ankle and foot bones in a 69-year-old man, a case study reported. His AS was discovered only after hospitalization for kidney problems and an examination for gout. The researchers suggested the terminology “boot sign”…
High levels of the pro-inflammatory molecule GM-CSF were found in the bloodstream of people with active ankylosing spondylitis (AS) and strongly correlated with disease activity, a pilot study suggested. Despite helping to lower disease activity, anti-TNF therapies did not affect GM-SCF levels. As such, GM-SCF may represent a…
Treatment with Cosentyx (secukinumab) leads to sustained reductions in symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) over one year, according to the Phase 3 PREVENT trial. These findings were the basis for Cosentyx’s recent approval…
Psoriasis in ankylosing spondylitis (AS) patients is not related to axial psoriatic arthritis (PsA), a type of psoriasis causing lower back inflammation and pain similar to AS, a new study has concluded. The results of the…
Anti-TNF therapies can halt disease progression and bone loss, and are associated with clinical improvement in people with ankylosing spondylitis after one year of treatment, a study shows. The study, “Effects of 1-year anti-TNF-α…
Get regular updates to your inbox.